SG11201903353WA - Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof - Google Patents
Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereofInfo
- Publication number
- SG11201903353WA SG11201903353WA SG11201903353WA SG11201903353WA SG11201903353WA SG 11201903353W A SG11201903353W A SG 11201903353WA SG 11201903353W A SG11201903353W A SG 11201903353WA SG 11201903353W A SG11201903353W A SG 11201903353WA SG 11201903353W A SG11201903353W A SG 11201903353WA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- international
- antigen presenting
- compositions
- reprogramming
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 7
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 5
- 210000004443 dendritic cell Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000008672 reprogramming Effects 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 101150005343 INHA gene Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/25—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from renal cells, from cells of the urinary tract
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT11001217 | 2017-04-05 | ||
EP17171166.6A EP3385373A1 (fr) | 2017-04-05 | 2017-05-15 | Compositions pour la reprogrammation de cellules en cellules dendritiques ou en cellules présentatrices d'antigènes, leurs procédés et utilisations |
PT11026317 | 2017-08-24 | ||
PT11026717 | 2017-08-25 | ||
PCT/IB2018/052378 WO2018185709A1 (fr) | 2017-04-05 | 2018-04-05 | Compositions destinées à la reprogrammation de cellules en cellules dendritiques ou en cellules présentatrices d'antigène, procédés et utilisations associés |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903353WA true SG11201903353WA (en) | 2019-05-30 |
Family
ID=63712920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903353WA SG11201903353WA (en) | 2017-04-05 | 2018-04-05 | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US11345891B2 (fr) |
EP (1) | EP3607055A1 (fr) |
JP (1) | JP7303743B2 (fr) |
CN (1) | CN110088272B (fr) |
CA (1) | CA3040626A1 (fr) |
IL (1) | IL266131A (fr) |
SG (1) | SG11201903353WA (fr) |
WO (1) | WO2018185709A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202112475QA (en) * | 2019-05-27 | 2021-12-30 | Univ Muenster Westfaelische Wilhelms | Rapid and deterministic generation of microglia from human pluripotent stem cells |
JP2023502318A (ja) * | 2019-10-10 | 2023-01-24 | アスガード セラピューティクス エービー | 細胞を再プログラム化して形質細胞様樹状細胞またはi型インターフェロン産生細胞に変換する組成物、その方法および用途 |
WO2021087234A1 (fr) * | 2019-11-01 | 2021-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reprogrammation de lignée en tant qu'immunothérapie anticancéreuse |
WO2021105234A1 (fr) * | 2019-11-25 | 2021-06-03 | Asgard Therapeutics Ab | Compositions destinées à la reprogrammation de cellules en cellules dendritiques de type 2 appropriées pour la présentation d'antigène, procédés et utilisations associés |
EP4076480A4 (fr) * | 2019-12-16 | 2024-04-17 | Washington University St Louis | Cellules dendritiques à récepteur antigénique chimérique (car-dc) et leurs procédés de fabrication et d'utilisation |
WO2021133775A1 (fr) * | 2019-12-23 | 2021-07-01 | University Of Florida Research Foundation, Incorporated | Immunothérapie pour la reprogrammation directe de cellules cancéreuses en cellules immunitaires/cellules présentatrices d'antigène/cellules dendritiques |
CN116888277A (zh) * | 2021-02-05 | 2023-10-13 | 杜克大学 | 检测和治疗真菌感染的方法 |
EP4341384A1 (fr) * | 2021-05-19 | 2024-03-27 | Asgard Therapeutics AB | Reprogrammation de cellules en cellules présentatrices d'antigènes ou cellules dendritiques conventionnelles de type 1 |
CN114252611B (zh) * | 2021-12-07 | 2022-09-27 | 暨南大学附属第一医院(广州华侨医院) | 一种筛选前列腺癌潜在生物标志物的方法及其应用 |
CN114324126B (zh) * | 2022-01-07 | 2024-03-19 | 南京鼓楼医院 | 一种改变早期b细胞分化的方法 |
WO2023176806A1 (fr) * | 2022-03-18 | 2023-09-21 | 国立研究開発法人産業技術総合研究所 | Procédé de reprogrammation de fibroblaste ou de cellule de type fibroblaste en cellule dendritique de type 2 classique |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0746994B2 (ja) | 1984-10-04 | 1995-05-24 | 味の素株式会社 | 発酵法によるl−アミノ酸の製造法 |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
CA2058820C (fr) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Cassettes d'expression et vecteurs pour la secretion de serum albumine humaine dans des cellules pichia pastoris |
WO1993011244A1 (fr) | 1991-11-29 | 1993-06-10 | Weyerhaeuser Company | Enzymes metaboliques cycliques de diguanylate |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
EP0672161B1 (fr) | 1992-11-05 | 1999-09-22 | Xyrofin Oy | Production de xylitol par recombinaison et hote utilise pour ce procede |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
EP0872547B1 (fr) | 1994-08-30 | 2007-12-26 | Ajinomoto Co., Inc. | Procede pour produire de la l-valine et de la l-leucine |
JP3966583B2 (ja) | 1997-06-23 | 2007-08-29 | 協和醗酵工業株式会社 | 発酵法によるl−アミノ酸の製造法 |
US8148129B2 (en) * | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
US9382515B2 (en) * | 2007-04-07 | 2016-07-05 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2010117879A1 (fr) * | 2009-04-08 | 2010-10-14 | Ld Biopharma, Inc. | Génération de cellules ips par transduction de protéine de facteurs déterminant la puissance recombinants |
CA3122219A1 (fr) | 2010-04-16 | 2011-10-20 | The Children's Hospital Corporation | Expression de polypeptide prolongee a partir d'arn synthetiques modifies et utilisations de celle-ci |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9228204B2 (en) * | 2011-02-14 | 2016-01-05 | University Of Utah Research Foundation | Constructs for making induced pluripotent stem cells |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20140378537A1 (en) * | 2011-09-09 | 2014-12-25 | Genentech, Inc. | Treatment of th17 mediated inflammatory diseases |
US9540612B2 (en) * | 2012-01-30 | 2017-01-10 | Icahn School Of Medicine At Mount Sinai | Methods for programming differentiated cells into hematopoietic stem cells |
US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
AU2014274840B2 (en) | 2013-06-05 | 2020-03-12 | Duke University | RNA-guided gene editing and gene regulation |
WO2016120651A1 (fr) * | 2015-01-30 | 2016-08-04 | Debreceni Egyetem | Génération améliorée dépendante de runx3 de cellules dendritiques |
WO2021087234A1 (fr) | 2019-11-01 | 2021-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Reprogrammation de lignée en tant qu'immunothérapie anticancéreuse |
-
2018
- 2018-04-05 CN CN201880005047.3A patent/CN110088272B/zh active Active
- 2018-04-05 CA CA3040626A patent/CA3040626A1/fr active Pending
- 2018-04-05 JP JP2019524083A patent/JP7303743B2/ja active Active
- 2018-04-05 SG SG11201903353WA patent/SG11201903353WA/en unknown
- 2018-04-05 US US16/342,803 patent/US11345891B2/en active Active
- 2018-04-05 WO PCT/IB2018/052378 patent/WO2018185709A1/fr unknown
- 2018-04-05 EP EP18723960.3A patent/EP3607055A1/fr active Pending
-
2019
- 2019-04-18 IL IL266131A patent/IL266131A/en unknown
-
2022
- 2022-04-26 US US17/729,681 patent/US20220325244A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110088272B (zh) | 2023-08-04 |
US11345891B2 (en) | 2022-05-31 |
US20220325244A1 (en) | 2022-10-13 |
US20200017832A1 (en) | 2020-01-16 |
JP2020513191A (ja) | 2020-05-07 |
WO2018185709A1 (fr) | 2018-10-11 |
EP3607055A1 (fr) | 2020-02-12 |
CA3040626A1 (fr) | 2018-10-11 |
CN110088272A (zh) | 2019-08-02 |
WO2018185709A9 (fr) | 2019-08-22 |
IL266131A (en) | 2019-06-30 |
JP7303743B2 (ja) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903353WA (en) | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201910173YA (en) | Device and method for microfluidics-based 3d bioprinting | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201807068WA (en) | Devices and methods for rapid pcr | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201909602TA (en) | Compositions and methods involving probiotic molecules | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201908337VA (en) | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201407802WA (en) | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201803642WA (en) | Bacteria-based protein delivery | |
SG11201810975UA (en) | Method for stabilizing proteins |